Sunder Biomedical Tech. Co., Ltd.(TW:4115)
NT$6.970.00 (0.00%)
TW:4115
Sunder Biomedical Tech. Co., Ltd. financials statements
NT$6.97
At close:0.00 (0.00%)
Sunder Biomedical Tech. Co., Ltd. (4115) Ratios
Sunder Biomedical Tech. Co., Ltd. Ratios
TW:4115's free cash flow for Q2 2026 was NT$-26.12M. For the 2026 fiscal year, TW:4115's free cash flow was decreased by NT$-48.88M and operating cash flow was NT$22.76M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.32 | 1.45 | 1.53 | 1.55 | 1.37 |
| Quick Ratio | 1.00 | 1.03 | 1.22 | 1.12 | 1.06 |
| Cash Ratio | 0.27 | 0.35 | 0.22 | 0.36 | 0.27 |
| Solvency Ratio | 0.14 | 0.21 | 0.11 | 0.19 | 0.23 |
| Operating Cash Flow Ratio | 0.19 | 0.29 | 0.11 | 0.28 | 0.38 |
| Short-Term Operating Cash Flow Coverage | 0.28 | 0.45 | 0.18 | 0.47 | 0.63 |
| Net Current Asset Value | NT$ -25.55M | NT$ 2.22M | NT$ -10.88M | NT$ -55.20M | NT$ -73.78M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.31 | 0.30 | 0.35 | 0.33 | 0.34 |
| Debt-to-Equity Ratio | 0.51 | 0.52 | 0.67 | 0.60 | 0.65 |
| Debt-to-Capital Ratio | 0.34 | 0.34 | 0.40 | 0.38 | 0.39 |
| Long-Term Debt-to-Capital Ratio | 0.15 | 0.16 | 0.23 | 0.22 | 0.21 |
| Financial Leverage Ratio | 1.68 | 1.69 | 1.91 | 1.80 | 1.89 |
| Debt Service Coverage Ratio | 0.30 | 0.49 | 0.31 | 0.55 | 0.60 |
| Interest Coverage Ratio | -1.94 | 2.20 | -2.99 | 1.47 | 8.81 |
| Debt to Market Cap | 0.76 | 0.63 | 0.53 | 0.42 | 0.30 |
| Interest Debt Per Share | 6.61 | 6.87 | 8.40 | 8.12 | 8.93 |
| Net Debt to EBITDA | 4.23 | 2.16 | 5.15 | 2.69 | 2.06 |
| Profitability Margins | |||||
| Gross Profit Margin | 13.60% | 18.53% | 10.12% | 13.34% | 17.62% |
| EBIT Margin | -2.43% | 5.39% | -3.64% | 2.18% | 8.51% |
| EBITDA Margin | 9.08% | 16.38% | 9.95% | 12.10% | 16.97% |
| Operating Profit Margin | -2.43% | 3.14% | -4.86% | 1.50% | 7.10% |
| Pretax Profit Margin | -3.42% | 3.97% | -5.26% | 1.16% | 7.70% |
| Net Profit Margin | -2.16% | 3.79% | -4.30% | 1.26% | 6.24% |
| Continuous Operations Profit Margin | -2.16% | 3.79% | -4.30% | 1.26% | 6.24% |
| Net Income Per EBT | 63.16% | 95.67% | 81.83% | 108.92% | 80.96% |
| EBT Per EBIT | 140.41% | 126.26% | 108.30% | 77.38% | 108.49% |
| Return on Assets (ROA) | -1.28% | 2.21% | -2.36% | 0.93% | 4.64% |
| Return on Equity (ROE) | -2.15% | 3.74% | -4.51% | 1.68% | 8.78% |
| Return on Capital Employed (ROCE) | -2.03% | 2.55% | -3.84% | 1.50% | 7.64% |
| Return on Invested Capital (ROIC) | -1.00% | 1.94% | -2.47% | 1.24% | 4.86% |
| Return on Tangible Assets | -1.28% | 2.21% | -2.36% | 0.94% | 4.64% |
| Earnings Yield | -3.21% | 4.62% | -3.66% | 1.25% | 4.24% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.13 | 3.36 | 3.10 | 4.31 | 3.99 |
| Payables Turnover | 19.48 | 12.91 | 15.37 | 18.08 | 14.32 |
| Inventory Turnover | 5.47 | 3.94 | 5.13 | 5.62 | 6.30 |
| Fixed Asset Turnover | 1.06 | 1.06 | 1.11 | 1.32 | 1.35 |
| Asset Turnover | 0.59 | 0.58 | 0.55 | 0.74 | 0.74 |
| Working Capital Turnover Ratio | 5.26 | 3.86 | 3.55 | 5.51 | 7.47 |
| Cash Conversion Cycle | 164.65 | 172.86 | 164.92 | 129.48 | 123.94 |
| Days of Sales Outstanding | 116.68 | 108.52 | 117.56 | 84.71 | 91.50 |
| Days of Inventory Outstanding | 66.71 | 92.60 | 71.11 | 64.95 | 57.92 |
| Days of Payables Outstanding | 18.74 | 28.27 | 23.75 | 20.19 | 25.48 |
| Operating Cycle | 183.39 | 201.13 | 188.67 | 149.67 | 149.42 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.17 | 1.80 | 0.79 | 1.74 | 2.96 |
| Free Cash Flow Per Share | -0.13 | 0.17 | -0.23 | 0.51 | 1.39 |
| Dividend Paid and CapEx Coverage Ratio | 0.90 | 1.10 | 0.60 | 0.95 | 1.58 |
| Capital Expenditure Coverage Ratio | 0.90 | 1.10 | 0.77 | 1.41 | 1.88 |
| Operating Cash Flow Coverage Ratio | 0.18 | 0.27 | 0.10 | 0.22 | 0.34 |
| Operating Cash Flow to Sales Ratio | 0.09 | 0.14 | 0.06 | 0.10 | 0.16 |
| Free Cash Flow Yield | -1.55% | 1.58% | -1.53% | 2.86% | 4.96% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -31.11 | 21.43 | -27.45 | 80.91 | 23.69 |
| Price-to-Sales (P/S) Ratio | 0.67 | 0.82 | 1.18 | 1.01 | 1.47 |
| Price-to-Book (P/B) Ratio | 0.67 | 0.81 | 1.23 | 1.35 | 2.07 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -64.41 | 63.12 | -65.51 | 34.93 | 20.17 |
| Price-to-Operating Cash Flow Ratio | 7.17 | 5.83 | 19.11 | 10.23 | 9.43 |
| Price-to-Earnings Growth (PEG) Ratio | 0.20 | -0.11 | 0.08 | -0.99 | 0.69 |
| Enterprise Value Multiple | 11.62 | 7.17 | 16.98 | 11.07 | 10.74 |
| Enterprise Value | 795.24M | 901.03M | 1.30B | 1.41B | 2.08B |
| EV to EBITDA | 11.62 | 7.17 | 16.98 | 11.07 | 10.74 |
| EV to Sales | 1.06 | 1.18 | 1.69 | 1.34 | 1.82 |
| EV to Free Cash Flow | -101.27 | 90.27 | -94.04 | 46.14 | 24.98 |
| EV to Operating Cash Flow | 11.27 | 8.33 | 27.43 | 13.51 | 11.67 |
| Tangible Book Value Per Share | 12.53 | 12.92 | 12.23 | 13.13 | 13.45 |
| Shareholders’ Equity Per Share | 12.59 | 12.96 | 12.26 | 13.17 | 13.48 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.37 | 0.04 | 0.18 | -0.09 | 0.19 |
| Revenue Per Share | 12.51 | 12.78 | 12.84 | 17.56 | 18.99 |
| Net Income Per Share | -0.27 | 0.48 | -0.55 | 0.22 | 1.18 |
| Tax Burden | 0.63 | 0.96 | 0.82 | 1.09 | 0.81 |
| Interest Burden | 1.40 | 0.74 | 1.45 | 0.53 | 0.91 |
| Research & Development to Revenue | 0.04 | 0.04 | 0.04 | 0.03 | 0.02 |
| SG&A to Revenue | 0.11 | 0.12 | 0.11 | 0.09 | 0.08 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -2.74 | 3.56 | -1.17 | 8.54 | 2.50 |
Currency in TWD
